Related Experiment Video
Updated: Aug 12, 2026
11:07
Biochemical Reconstitution of Steroid Receptor•Hsp90 Protein Complexes and Reactivation of Ligand Binding
Published on: September 21, 2011
New glucocorticoids on the horizon: repress, don't activate!
In-Ho Song1, Ralf Gold, Rainer H Straub
1Department of Rheumatology and Clinical Immunology, Charité University Hospital, Berlin, Germany. frank.buttgereit@charite.de
The Journal of Rheumatology
|July 27, 2005
Summary
New glucocorticoid drugs aim to improve treatment for inflammatory diseases by reducing side effects. Research focuses on selective agonists, nitrosteroids, and liposomal formulations for better therapeutic outcomes.
Area of Science:
- Pharmacology
- Immunology
- Drug Development
Background:
- Glucocorticoids are effective anti-inflammatory and immunosuppressive drugs used for rheumatic and other inflammatory conditions.
- Adverse reactions often limit the clinical use of conventional glucocorticoids.
- Developing novel glucocorticoids with an improved therapeutic effect-to-adverse reaction ratio is a key research objective.
Purpose of the Study:
- To review and critically discuss emerging glucocorticoid therapies under development.
- To explore innovative approaches for targeted glucocorticoid action.
- To summarize research on novel glucocorticoid receptor ligands and targets.
Main Methods:
- Literature review and critical analysis of ongoing research in glucocorticoid drug development.
- Discussion of selective glucocorticoid receptor agonists (SEGRA), nitrosteroids, and liposomal glucocorticoids.
- Examination of research on membrane-bound glucocorticoid receptors.
Main Results:
- Several innovative glucocorticoid strategies are under development, including SEGRA, nitrosteroids, and liposomal formulations.
- These novel approaches aim to enhance therapeutic efficacy while minimizing adverse effects.
- Research into membrane-bound glucocorticoid receptors suggests new avenues for targeted glucocorticoid therapies.
Conclusions:
- Novel glucocorticoid therapies show promise for improving the treatment of inflammatory diseases.
- Selective glucocorticoid receptor agonists, nitrosteroids, and liposomal formulations represent key areas of advancement.
- Further research into novel targets like membrane-bound receptors may lead to more specific and safer glucocorticoid treatments.
Related Concept Videos
02:04Co-activators and Co-repressors
Gene transcription is regulated by the synergistic action of several proteins that form a complex at a gene regulatory site. This is observed in eukaryotes, where the regulation of gene expression is a complex process. Regulatory proteins in eukaryotes can broadly be classified into two types – regulators that bind directly to specific DNA sequences and co-regulators that associate with regulatory proteins but cannot directly bind to the DNA. These co-regulators are further divided into...
01:09GPCRs Regulate Adenylyl Cylase Activity
Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of cells.
Two...
Two...
01:31Transducer Mechanism: Nuclear Receptors
Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
01:25Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...